Comparative Pharmacology
Head-to-head clinical analysis: CLOZARIL versus RISPERIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOZARIL versus RISPERIDONE.
CLOZARIL vs RISPERIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clozapine is an atypical antipsychotic that binds to multiple receptors including dopamine D1-D5 (with greater affinity for D4), serotonin 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, 5-HT7, histamine H1, muscarinic M1-M5, and adrenergic α1- and α2-receptors. Its therapeutic efficacy is primarily attributed to antagonism of D2 and 5-HT2A receptors. It also has weak D2 antagonism and rapid dissociation from D2 receptors, which may contribute to lower extrapyramidal side effects.
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.
Initial 12.5 mg orally once or twice daily, titrate by 25-50 mg/day over 2 weeks to target 300-450 mg/day in divided doses; max 900 mg/day.
Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.
None Documented
None Documented
Clinical Note
moderateRisperidone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone propionate."
Clinical Note
moderateRisperidone + Methylphenidate
"The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate."
Clinical Note
moderateRisperidone + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Risperidone."
Clinical Note
moderateTerminal elimination half-life is approximately 8–12 hours at steady state; range 6–26 hours, increasing with dose due to saturable metabolism.
Risperidone: 3 hours (CYP2D6 extensive metabolizers), 20 hours (poor metabolizers); active metabolite 9-hydroxyrisperidone: 21-30 hours; steady-state reached in 5-6 days
Approximately 50% excreted renally as metabolites, with less than 1% unchanged; 30% eliminated in feces via biliary excretion.
Renal (70% as metabolites, 14% as parent drug) and fecal (14%)
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic
Risperidone + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Risperidone."